Simen et al.84evaluated the impact of the rapamycin, an mTOR inhibitor and autophagy stimulator, on the tau‐mediated neurodegeneration and synaptic loss in a mouse model of early‐stage AD‐type tauopathy. The gene discussed is MAPT; the disease is tauopathy.